Kiniksa Pharmaceuticals International, plc 8-K

What Happened

• Kiniksa Pharmaceuticals International plc held its Annual Meeting of Shareholders on May 29, 2026 (record date April 6, 2026). A quorum was present. Class A shares carried one vote per share and Class B shares carried ten votes per share.
• All proposals presented at the meeting were approved. Class II director nominees Stephen R. Biggar, G. Bradley Cole and Barry D. Quart were re‑elected. Vote totals for the director elections were:
  • Stephen R. Biggar: 37,474,114 FOR; 11,999,916 AGAINST; 13,825 ABSTAINED; 4,425,771 broker non‑votes
  • G. Bradley Cole: 48,299,818 FOR; 1,174,991 AGAINST; 13,046 ABSTAINED; 4,425,771 broker non‑votes
  • Barry D. Quart: 48,061,571 FOR; 1,413,338 AGAINST; 12,946 ABSTAINED; 4,425,771 broker non‑votes

Key Details

• PwC was approved as the Company’s UK statutory auditors (Proposal 2: 53,857,053 FOR; 48,432 AGAINST; 8,141 ABSTAINED) and was ratified as the U.S. independent registered public accounting firm for FY2026 (Proposal 3: 53,857,126 FOR; 48,355 AGAINST; 8,145 ABSTAINED).
• The board’s audit committee was authorized to determine PwC’s remuneration as UK statutory auditors (Proposal 4: 53,890,585 FOR; 12,498 AGAINST; 10,543 ABSTAINED).
• Shareholder votes on UK statutory annual accounts and remuneration matters:
  • Receive UK statutory annual account/report for year ended Dec 31, 2025 (Proposal 5: 53,611,179 FOR; 2,032 AGAINST; 300,415 ABSTAINED).
  • Advisory (non‑binding) vote on Directors’ Annual Remuneration Report (Proposal 6: 48,353,142 FOR; 1,104,811 AGAINST; 29,902 ABSTAINED; 4,425,771 broker non‑votes).
  • Approval of UK Statutory Directors’ Remuneration Policy (Proposal 7: 48,633,937 FOR; 824,799 AGAINST; 29,119 ABSTAINED; 4,425,771 broker non‑votes).
  • Advisory (non‑binding) approval of named executive officers’ compensation (Proposal 8: 48,145,082 FOR; 1,334,278 AGAINST; 8,495 ABSTAINED; 4,425,771 broker non‑votes).

Why It Matters

• Board continuity: Re‑election of the three Class II directors keeps existing management oversight in place through the 2029 Annual Meeting (subject to resignations or replacements).
• Auditors confirmed: Ratification of PwC for UK and U.S. audit roles provides continuity for the company’s statutory and U.S. audit processes for the coming year.
• Shareholder sentiment: Several compensation‑related proposals were advisory (non‑binding) and passed, but notable vote totals and approximately 4.43 million broker non‑votes were recorded on director and remuneration items — important context for management and investors tracking governance and executive pay issues.